EyeGate Pharmaceuticals Inc (EYEG)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:EyeGate Pharmaceuticals Inc (EYEG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014019
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical company that offers eye care medicines. The company offers macular edema and non-infectious anterior uveitis. It offers technologies for most prevalent issues in ophthalmic care; the existing lack of patient adherence and patient safety. EyeGate deliver drugs in optimal dosing regimens directly into the ocular tissue in both the anterior and posterior segments of the eye. The company offers EGP-437 that incorporates a reformulated corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues. It also offers drug delivery mechanisms for treating diseases of the eye. EyeGate is headquartered in Waltham, Massachusetts, the US.

EyeGate Pharmaceuticals Inc (EYEG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
EyeGate Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
EyeGate Pharma Raises USD2.6 Million in Venture Financing 13
EyeGate Pharma Raises USD1 Million in Venture Financing 14
Jade Therapeutics To Raise US$0.6 Million In Venture Financing 15
EyeGate Pharma Raises US$1 Million In Venture Financing 16
EyeGate Pharma Secures An Additional US$5.9 Million In Series D Round Of Financing 17
Partnerships 18
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 18
Licensing Agreements 20
EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 20
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 21
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 22
Equity Offering 23
EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 23
EyeGate Pharma Raises USD3.8 Million in Private Placement of Shares and Preferred Stock 24
EyeGate Pharma Raises USD10 Million in Public Offering of Shares 26
EyeGate Pharma Raises USD4.1 Million in IPO 28
Acquisition 30
Eyegate Pharma Acquires Jade Therapeutics 30
EyeGate Pharmaceuticals Inc – Key Competitors 31
EyeGate Pharmaceuticals Inc – Key Employees 32
EyeGate Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 14, 2017: EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update 34
Aug 07, 2017: EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 36
May 08, 2017: EyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 37
Feb 23, 2017: EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update 39
Nov 02, 2016: EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update 40
Aug 10, 2016: EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update 41
May 13, 2016: Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update 43
Mar 29, 2016: EyeGate Reports Full-year 2015 Financial Results and Provides Business Update 45
Corporate Communications 46
Nov 01, 2017: EyeGate Appoints Mike Garanzini as Chief Commercial Officer to Develop and Implement Global Launch Strategy 46
Oct 23, 2017: Eye Care Thought Leaders Join EyeGate Scientific Advisory Board 47
Feb 06, 2017: EyeGate Pharmaceuticals Announces Executive Promotions 48
Apr 27, 2016: EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer 49
Government and Public Interest 50
Sep 13, 2016: EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
EyeGate Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
EyeGate Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
EyeGate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
EyeGate Pharma Raises USD2.6 Million in Venture Financing 13
EyeGate Pharma Raises USD1 Million in Venture Financing 14
Jade Therapeutics To Raise US$0.6 Million In Venture Financing 15
EyeGate Pharma Raises US$1 Million In Venture Financing 16
EyeGate Pharma Secures An Additional US$5.9 Million In Series D Round Of Financing 17
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 18
EyeGate Pharma Enters into Licensing Agreement with University Of Utah Research Foundation 20
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 21
BioTime Enters Into Licensing Agreement With Jade Therapeutics For HyStem 22
EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 23
EyeGate Pharma Raises USD3.8 Million in Private Placement of Shares and Preferred Stock 24
EyeGate Pharma Raises USD10 Million in Public Offering of Shares 26
EyeGate Pharma Raises USD4.1 Million in IPO 28
Eyegate Pharma Acquires Jade Therapeutics 30
EyeGate Pharmaceuticals Inc, Key Competitors 31
EyeGate Pharmaceuticals Inc, Key Employees 32
EyeGate Pharmaceuticals Inc, Subsidiaries 33

★海外企業調査レポート[EyeGate Pharmaceuticals Inc (EYEG)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Westlake Chemical Corporation:企業の戦略・SWOT・財務情報
    Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report Summary Westlake Chemical Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • U-Shin Ltd.:企業の戦略的SWOT分析
    U-Shin Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Yale School of Medicine-製薬・医療分野:企業M&A・提携分析
    Summary Yale School of Medicine (YSM), a subsidiary of Yale University is an educational service provider that offers bio-medical research, education and advanced health care. The center provides degree programs such as public health program, physician associate program, other PhD programs, medical …
  • Saturn Oil & Gas Inc (SMI):石油・ガス:M&Aディール及び事業提携情報
    Summary Saturn Oil & Gas Inc (Saturn) formerly Saturn Minerals Inc, is a mineral exploration company that acquires, explores and develops oil and gas, potash and coal resources. The company’s oil and gas project is situated between the towns of Tisdale and Hudson Bay in Eastern Saskatchewan. It prov …
  • JAFCO Co., Ltd.:企業のM&A・事業提携・投資動向
    JAFCO Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JAFCO Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Agios Pharmaceuticals Inc (AGIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 …
  • National Institute of Neurological Disorders and Stroke-製薬・医療分野:企業M&A・提携分析
    Summary National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute’s clinical research areas include Alzheimer’s disease, br …
  • Accrol Group Holdings PLC (ACRL):企業の財務・戦略的SWOT分析
    Accrol Group Holdings PLC (ACRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • AusGroup Ltd (5GJ):石油・ガス:M&Aディール及び事業提携情報
    Summary AusGroup Ltd (AusGroup) is a provider of project and asset services. The company operates through its subsidiaries, namely, MAS, AGC, and NT Port and Marine. Its major services include mechanical and piping, scaffolding, multidisciplinary maintenance services, fabrication & management, surfa …
  • SPX Corp (SPXC):企業の財務・戦略的SWOT分析
    SPX Corp (SPXC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • SPIE SA (SPIE):電力:M&Aディール及び事業提携情報
    Summary SPIE SA (SPIE) provides multi-technical services in the areas of energy and communications. The company designs, builds, operates and maintains energy efficient and environmental facilities. It provides various products and services for developing efficient buildings. Its service offerings i …
  • NVIDIA Corp (NVDA):企業の財務・戦略的SWOT分析
    NVIDIA Corp (NVDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Berjaya Corporation Berhad (BJCORP):企業の財務・戦略的SWOT分析
    Berjaya Corporation Berhad (BJCORP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Technicolor SA:企業の戦略・SWOT・財務情報
    Technicolor SA - Strategy, SWOT and Corporate Finance Report Summary Technicolor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Oxford Gene Technology Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford Gene Technology Ltd (OGT) is a provider of genetics research solutions. The company’s products comprise fish probes, custom cancer panels, custom AML panel, custom breast cancer panel, custom FH panel, core MPN panel, ovarian cancer panel, myeloid panel and others. It provides medical …
  • Tesco Mobile Limited:企業の戦略的SWOT分析
    Tesco Mobile Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Public Power Corporation SA:発電所・企業SWOT分析
    Public Power Corporation SA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Abu Dhabi Commercial Bank P.J.S.C.:企業の戦略・SWOT・財務情報
    Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Fonterra Co-operative Group Ltd:企業の戦略・SWOT・財務情報
    Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Fonterra Co-operative Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Itamar Medical Ltd (ITMR):企業の財務・戦略的SWOT分析
    Summary Itamar Medical Ltd (Itamar Medical) is a medical device company that develops, manufactures, and markets non-invasive medical devices for the diagnosis of cardiology disease and sleep related breathing disorders. The company develops products using its proprietary peripheral arterial tonomet …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆